Overview
Kerion, a severe inflammatory and suppurative dermatophyte infection typically caused by Trichophyton species, manifests as a painful, boggy, and often nodular lesion on the scalp or other hairy regions. This condition is clinically significant due to its potential for significant scarring and alopecia, impacting both physical appearance and psychological well-being. Primarily affecting children and immunocompromised individuals, kerion underscores the importance of early recognition and intervention to prevent long-term sequelae. Understanding kerion is crucial in day-to-day practice for timely diagnosis and effective management to mitigate complications and improve patient outcomes 19.Pathophysiology
Kerion results from a robust immune response to dermatophyte invasion, particularly by Trichophyton species such as T. tonsurans, T. mentagrophytes, and T. violaceum. The fungal hyphae penetrate the stratum corneum, triggering a cascade of inflammatory reactions involving neutrophils, macrophages, and lymphocytes. This immune activation leads to the characteristic hypertrophic and suppurative changes observed clinically. At the cellular level, keratinocytes and fibroblasts are activated, contributing to the formation of a dense inflammatory infiltrate and the accumulation of exudate, which characterizes the boggy nature of kerion lesions. Additionally, the presence of inflammatory cytokines such as TNF-α and IL-1β exacerbates tissue damage and impedes normal wound healing processes, potentially leading to scarring and alopecia 14.Epidemiology
Kerion is more prevalent in children and immunocompromised individuals, though it can occur in any age group. Incidence rates vary geographically, with higher prevalence reported in tropical and subtropical regions due to favorable environmental conditions for fungal growth. No specific sex predilection is noted, but certain populations, such as those with close scalp contact (e.g., school settings), may experience higher exposure rates. Trends suggest an increasing awareness and reporting of kerion cases, possibly due to improved diagnostic techniques and heightened clinical vigilance. However, precise global incidence and prevalence figures are limited, highlighting the need for more comprehensive epidemiological studies 19.Clinical Presentation
Kerion typically presents with well-demarcated, erythematous, tender, and swollen plaques often centered on hair follicles, leading to patchy alopecia. Patients commonly report intense itching, pain, and the presence of pustules or sinuses draining purulent material. Atypical presentations may include less pronounced inflammation or atypical locations, such as the beard area in men. Red-flag features include rapid progression, systemic symptoms like fever, and signs of superinfection, which necessitate urgent evaluation and management to prevent complications such as secondary bacterial infections or extensive scarring 19.Diagnosis
The diagnosis of kerion involves a combination of clinical evaluation and confirmatory laboratory tests. Clinically, the characteristic appearance of boggy, tender, and often nodular lesions with associated alopecia is highly suggestive. Definitive diagnosis relies on:Differential Diagnosis:
Management
First-Line Treatment
Monitoring: Regular clinical follow-up to assess response and manage side effects.
Second-Line Treatment
Monitoring: Close monitoring for drug interactions and adverse effects, particularly in immunocompromised patients.
Refractory or Specialist Escalation
Contraindications: Avoid oral antifungals in patients with severe liver dysfunction or known drug allergies 19.
Complications
Prognosis & Follow-up
The prognosis for kerion is generally good with appropriate and timely treatment, though scarring and alopecia can be long-lasting complications. Prognostic indicators include the extent of the lesion, duration of untreated disease, and patient compliance with therapy. Recommended follow-up intervals are typically every 2-4 weeks initially, tapering to monthly visits until resolution, followed by periodic reassessment to monitor for recurrence or scarring 19.Special Populations
Key Recommendations
References
1 Geer DJ, Swartz DD, Andreadis ST. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo. The American journal of pathology 2005. link61242-4) 2 Wang X, Zinkel S, Polonsky K, Fuchs E. Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy. Proceedings of the National Academy of Sciences of the United States of America 1997. link 3 Guy RH, Kuma H, Nakanishi M. Serious photocontact dermatitis induced by topical ketoprofen depends on the formulation. European journal of dermatology : EJD 2014. link 4 Nassiri M, Woolery-Lloyd H, Ramos S, Jacob SE, Gugic D, Viciana A et al.. Gene expression profiling reveals alteration of caspase 6 and 14 transcripts in normal skin of keloid-prone patients. Archives of dermatological research 2009. link 5 Devleeschouwer V, Roelandts R, Garmyn M, Goossens A. Allergic and photoallergic contact dermatitis from ketoprofen: results of (photo) patch testing and follow-up of 42 patients. Contact dermatitis 2008. link 6 Matthieu L, Meuleman L, Van Hecke E, Blondeel A, Dezfoulian B, Constandt L et al.. Contact and photocontact allergy to ketoprofen. The Belgian experience. Contact dermatitis 2004. link 7 Moser J, Sarabia Z, Minter H, Lovell WW, van Henegouwen GM. Photobinding of ketoprofen in vitro and ex vivo. Journal of photochemistry and photobiology. B, Biology 2000. link00111-1) 8 Albès B, Marguery MC, Schwarze HP, Journé F, Loche F, Bazex J. Prolonged photosensitivity following contact photoallergy to ketoprofen. Dermatology (Basel, Switzerland) 2000. link 9 Smitka TA, Bunge RH, Bloem RJ, French JC. Two new trichothecenes, PD 113,325 and PD 113,326. The Journal of antibiotics 1984. link